Wizel B, Houghten R A, Parker K C, Coligan J E, Church P, Gordon D M, Ballou W R, Hoffman S L
Malaria Program, Naval Medical Research Institute, Bethesda, Maryland 20889, USA.
J Exp Med. 1995 Nov 1;182(5):1435-45. doi: 10.1084/jem.182.5.1435.
Vaccines designed to protect against malaria by inducing CD8+ cytotoxic T lymphocytes (CTL) in individuals of diverse HLA backgrounds must contain multiple conserved epitopes from various preerythrocytic-stage antigens. Plasmodium falciparum sporozoite surface protein 2 (PfSSP2) is considered an important antigen for inclusion in such vaccines, because CD8+ CTL against the P. yoelii SSP2 protect mice against malaria by eliminating infected hepatocytes. To develop PfSSP2 as a component of malaria vaccines, we investigated the presence of anti-PfSSP2 CTL in two HLA-B8+ volunteers immunized with irradiated P. falciparum sporozoites and characterized their CTL responses using PfSSP2-derived 15-amino acid peptides bearing the HLA-B8-binding motif. Peripheral blood mononuclear cells from both volunteers stimulated with recombinant vaccinia expressing PfSSP2 displayed antigen-specific, genetically restricted, CD8+ T cell-dependent CTL activity against autologous target cells expressing PfSSP2. Of the five HLA-B8 motif-bearing 15-mers identified in the PfSSP2 sequence, two peptides sharing a 10-amino acid overlap sensitized HLA-B8-matched target cells from both volunteers for lysis by peptide-stimulated effectors. The CTL activity was HLA-B8 restricted and dependent on CD8+ T cells. Analysis of the three shorter peptides representing HLA-B8 motif-bearing sequences within the two positive peptides for their ability to bind to HLA-B8 in vitro, and to sensitize target cells for lysis by effectors stimulated with the 15-mers, identified two overlapping HLA-B8-restricted CTL epitopes. Available data indicate that the sequence of one CTL epitope is conserved and the other is variant among P. falciparum isolates. Circulating activated CTL against the conserved epitope could be directly identified in one of the two volunteers. The identification of two HLA-B8-restricted CTL epitopes on PfSSP2 provides data critical to developing an epitope-based anti-liver stage malaria vaccine.
旨在通过在不同HLA背景个体中诱导CD8 + 细胞毒性T淋巴细胞(CTL)来预防疟疾的疫苗必须包含来自各种红细胞前期抗原的多个保守表位。恶性疟原虫子孢子表面蛋白2(PfSSP2)被认为是此类疫苗中的一种重要抗原,因为针对约氏疟原虫SSP2的CD8 + CTL通过消除受感染的肝细胞来保护小鼠免受疟疾侵害。为了将PfSSP2开发为疟疾疫苗的一个组成部分,我们研究了两名接种辐照恶性疟原虫子孢子的HLA - B8 + 志愿者体内抗PfSSP2 CTL的存在情况,并使用带有HLA - B8结合基序的PfSSP2衍生的15个氨基酸的肽来表征他们的CTL反应。两名志愿者的外周血单核细胞用表达PfSSP2的重组痘苗刺激后,对表达PfSSP2的自体靶细胞表现出抗原特异性、基因限制性、CD8 + T细胞依赖性的CTL活性。在PfSSP2序列中鉴定出的五个带有HLA - B8基序的15肽中,两个有10个氨基酸重叠的肽使两名志愿者的HLA - B8匹配靶细胞对肽刺激的效应细胞的裂解敏感。CTL活性受HLA - B8限制且依赖于CD8 + T细胞。分析代表两个阳性肽中带有HLA - B8基序序列的三个较短肽在体外与HLA - B8结合的能力,以及使靶细胞对15肽刺激的效应细胞的裂解敏感的能力,确定了两个重叠的HLA - B8限制性CTL表位。现有数据表明,一个CTL表位的序列在恶性疟原虫分离株中是保守的,另一个是可变的。在两名志愿者中的一名中可以直接鉴定出针对保守表位的循环活化CTL。在PfSSP2上鉴定出两个HLA - B8限制性CTL表位为开发基于表位的抗肝期疟疾疫苗提供了关键数据。